



## Q4 | 2023 Newsletter

Dear Friend of Navigation Sciences,

I hope you enjoyed the holidays and that 2024 is off to a good start. Our focus in the fourth quarter and the New Year is on the user interface (UX) of the NaviSci™ System's software, finalizing the J-Bar delivery system, quality system for FDA compliance, and completing the Series B financing.

### New Addition to the Product Development Team

Steve Gemmell, a medical device product development and commercialization expert, recently joined Navigation Sciences to lead software development and systems integration for the NaviSci System. His experience in product development, project management, quality management systems, and regulatory submissions will be a great addition to our team. Steve will work closely with Larry Roth, who has been leading engineering and the development of the NaviSci EndoMarker™.

Steve brings over 20 years of experience in R&D and Operations roles at Insulet Corporation, Onduo, Cytrellis Biosystems, Haemonetics, and multiple startups. He started his career as a software systems engineer developing blood processing equipment and infusion pumps. He and his teams have designed and launched several very successful products in the diabetes, drug delivery, and surgical markets.

### Series B Financing

Our efforts are continuing to complete the planned \$5 million Series B to advance the NaviSci™ System to an FDA submission. Discussions with several potential investors are ongoing. We have already closed on over \$3 million of the \$5 million round.

We are encouraged by the support we have received to date and the increasing clarity around the scope of opportunity for the NaviSci System. The System is well positioned to capitalize on growth in early-stage lung cancer diagnoses and the emergence of minimally invasive, tissue-sparing surgery for lung and other soft tissue tumors.

Below are links to our white paper outlining the opportunity for Navigation Sciences in the new "era of precision cancer surgery," an updated company Executive Summary and corporate presentation. We have also updated the website.



**Navigation Sciences  
Executive Summary**



**Entering the Era of  
"Precision Cancer Surgery"**



**Navigation Sciences  
Corporate PPT**

As always, thank you for your support.

Sincerely,

Alan Lucas, CEO, Navigation Sciences, Inc.  
Alan.lucas@navigationsci.com  
+1-617-834-2829



[Visit Our Website](#)